Clinical Trials Browser

Phase 3 × Has announcements × Prednisone × Clear all

NCT03748641 2026-06-05

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-06-05

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

488 enrolled 13 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03274492 2026-05-08

POLARIX

Phase 3 Completed

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03589326 2025-11-26

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Phase 3 Active not recruiting

245 enrolled 15 charts 1 FDA

LymphoidOther hematologic neoplasm

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Phase 3 Completed

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT01777152 2021-11-30

ECHELON-2

Phase 3 Completed

452 enrolled 16 charts 1 FDA

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic